The Business of Biofabrication

Aspect Biosystems, a biotechnology leader in bioprinted tissue therapeutics, has announced the successful close of a $115 million Series B funding round. The financing, led by Dimension—a firm specializing in technology and life sciences—featured contributions from a diverse group of investors, including Novo Nordisk, Radical Ventures, InBC, and others. This round marks a significant step forward in Aspect’s mission to develop functional cures for serious diseases and expand its bioprinted tissue therapeutic platform.

The Series B funding builds on Aspect’s recent milestones, including a CA$200 million collaboration with the governments of Canada and British Columbia and a partnership with Novo Nordisk targeting diabetes and obesity. Proceeds from the financing will accelerate clinical development of Aspect’s bioprinted tissue therapeutics and further strengthen its platform, which integrates AI-powered bioprinting, computational design tools, therapeutic cells, and advanced biomaterials.

“We are thrilled to partner with Dimension and this exceptional investor group,” said Tamer Mohamed, Founder and CEO of Aspect Biosystems. “Their support enables us to deliver on our mission of transforming patient outcomes through disease-modifying treatments.”

The Development of New Cellular Medicines

Aspect’s work centers on developing bioprinted tissues to address complex metabolic and endocrine diseases such as diabetes, obesity, and rare disorders. The company’s full-stack platform is designed to replace, repair, or enhance biological functions inside the body, creating what it calls a “new class of cellular medicines.”

Nan Li, Founder and Managing Partner of Dimension, highlighted the transformative potential of Aspect’s technology: “Aspect is a multidisciplinary pioneer integrating tissue engineering, cell therapy, and advanced biomaterials. We are excited to partner with them to advance regenerative medicine.”

As part of the Series B financing, Nan Li has joined Aspect Biosystems’ Board of Directors.

Strategic Collaborations and a Robust Pipeline

Aspect’s pipeline development strategy blends proprietary programs with strategic partnerships. Its collaboration with Novo Nordisk exemplifies its focus on tackling global health challenges through innovative tissue engineering.

About Aspect Biosystems

Aspect Biosystems is a leader of bioprinted tissue therapeutics, developing next-generation cell therapies to address diseases that have long eluded conventional treatments. With a growing portfolio in metabolic and endocrine diseases, the company continues to work to push the boundaries of regenerative medicine through strategic partnerships and bioprinting technology.

For more information, visit Aspect Biosystems.